BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12119888)

  • 1. [Coxib spares the stomach. This is true also for patients with preventive aspirin administration].
    MMW Fortschr Med; 2002 May; 144(20):62. PubMed ID: 12119888
    [No Abstract]   [Full Text] [Related]  

  • 2. [When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
    Zeidler H
    MMW Fortschr Med; 2003 Jan; 145(5):8. PubMed ID: 12619198
    [No Abstract]   [Full Text] [Related]  

  • 3. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?].
    MMW Fortschr Med; 2002 Apr; 144(14):53. PubMed ID: 12014284
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
    Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
    Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 8. [Celecoxib and the CLASS study--worse and worse...].
    Slørdal L
    Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903
    [No Abstract]   [Full Text] [Related]  

  • 9. [Celebrex: confirmed effectiveness and safety (new data)].
    Nasonov EL
    Ter Arkh; 2001; 73(5):57-61. PubMed ID: 11517753
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].
    MMW Fortschr Med; 2002 Jul; 144(29-30):52. PubMed ID: 12219613
    [No Abstract]   [Full Text] [Related]  

  • 11. A safe non-steroidal anti-inflammatory drug--the search continues.
    Lanza FL
    Ital J Gastroenterol Hepatol; 1999; 31(5):386-7. PubMed ID: 10470597
    [No Abstract]   [Full Text] [Related]  

  • 12. [Celecoxib and the CLASS study--a statement].
    Wibe E; Maehlum S
    Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2218. PubMed ID: 12426902
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
    Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
    Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misoprostol (Cytotec) in NSAID gastropathy.
    Habibullah CM; Singh SP; Phaterpekar SJ
    J Assoc Physicians India; 1993 Nov; 41(11):770. PubMed ID: 8005958
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Sebaldt RJ; Kremer J
    Arthritis Rheum; 2005 Feb; 53(1):12-7. PubMed ID: 15696570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 17. [Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].
    Tsurko VV; Preobrazhenskiĭ DV; Ob ukhova OA
    Ter Arkh; 2003; 75(5):64-70. PubMed ID: 12847902
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The future of peptic ulcer disease without Helicobacter].
    Lehmann FS; Gyr N
    Praxis (Bern 1994); 2003 Mar; 92(12):547-50. PubMed ID: 12693146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.